Skip to content

An exploratory study on the pathogenesis of primary Sjogren's syndrome

An exploratory study on the biomarker of primary Sjogren's syndrome

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000039820
Enrollment
Unknown
Registered
2020-11-10
Start date
2020-12-01
Completion date
Unknown
Last updated
2022-09-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary Sjogren syndrome

Interventions

PSS patient group:No intervention
Healthy control group:No interwention

Sponsors

Department of Stomatology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: The subjects should meet the following criteria: pSS patient group: 1. Signed informed consent form with date 2. Commitment to abide by the research procedures, and cooperate with the implementation of the whole process of research 3. Men and women are not limited, age is not limited to 4. All the pSS patients enrolled in this study met the American Rheumatic Association ((ACR))-European Alliance against Rheumatism ((EULAR)) criteria. Non-pSS:1. was excluded from drug use, diabetes, hypertension, infection and other diseases. Signed informed consent form with date 2. Commitment to abide by the research procedures, and cooperate with the implementation of the whole process of research 3. Men and women are not limited, age is not limited to 4. The age matched that of the experimental group. The patients in this group were composed of patients who underwent minor lip surgery and lip trauma treatment, and then pSS was excluded by pathological examination.

Exclusion criteria

Exclusion criteria: Subjects who meet any of the following criteria will be excluded from this study: 1. Specific disallowed drugs are currently being used. 2. Be in pregnancy or lactation period 3. There are febrile diseases in a specific period of time. 4. Treatment with other experimental drugs within a specific period of time. 5. With specified diseases or conditions excluded from the study (physical or psychological, physical findings).

Design outcomes

Primary

MeasureTime frame
biomark;antinuclear antibodies;anti-SSA antibody;anti-SSB antibody;rheumatoid factors;Erythrocyte sedimentation rate;C reactive protein;immunoglobulin G;immunoglobulin A;immunoglobulin M;complement 3;complement 4;

Countries

China

Contacts

Public ContactGao Yiming

Ruijin Hospital, Shanghai Jiaotong University School of Medicine

drgaoym@163.com+86 13817507317

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026